Work

Elevated serum KIF20A in hepatocellular carcinoma: exploring its potential as a circulating biomarker

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Aims: To evaluate serum KIF20A expression in hepatocellular carcinoma (HCC) and assess its association with HCC status using a bioinformatics-guided clinical RT-qPCR approach. Methods: This cross-sectional study included 110 participants: 50 with HCC, 10 with chronic hepatitis C virus (HCV) infection without HCC, and 50 healthy controls. Serum hsa-miR-5192, HSPA1B, LPH02229A/CRHR1-IT1, and KIF20A were quantified by RT-qPCR as relative quantification (RQ). Alpha-fetoprotein (AFP) was the conventional comparator. Secondary analyses evaluated AFP with KIF20A using logistic regression, AUC comparison, and repeated stratified 10-fold cross-validation. Results: KIF20A showed significant overall differential expression (P=0.003), with higher expression in HCC than in healthy controls (P=0.007) and the HCV non-HCC group (P=0.004). Median KIF20A RQ was 2.95 in HCC, 0.40 in healthy controls, and 0.255 in HCV. For HCC versus all non-HCC participants, KIF20A remained associated with HCC after accounting for AFP (OR 2.10 per 1-SD increase in log-transformed KIF20A; 95% CI 1.01-4.37; P=0.048), but the combined model did not materially improve discrimination over AFP alone (AUC 0.968 vs 0.964; DeLong P=0.606). Conclusions: Serum KIF20A showed HCC-associated upregulation and retained an exploratory association with HCC after accounting for AFP. However, it did not provide meaningful incremental discrimination beyond AFP; the small disease-control group and absence of external validation preclude claims of HCC specificity or clinical diagnostic readiness.
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7236578450
FWCI:
Cites: 24
Cited by:
Related to: 10